Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Inactivation of the Saccharomyces cerevisiae SKY1Gene Induces a Specific Modification of the Yeast Anticancer Drug Sensitivity Profile Accompanied by a Mutator Phenotype

Paul W. Schenk, Antonius W. M. Boersma, Mariël Brok, Herman Burger, Gerrit Stoter and Kees Nooter
Molecular Pharmacology March 2002, 61 (3) 659-666; DOI: https://doi.org/10.1124/mol.61.3.659
Paul W. Schenk
Department of Medical Oncology, University Hospital Rotterdam–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonius W. M. Boersma
Department of Medical Oncology, University Hospital Rotterdam–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariël Brok
Department of Medical Oncology, University Hospital Rotterdam–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Herman Burger
Department of Medical Oncology, University Hospital Rotterdam–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerrit Stoter
Department of Medical Oncology, University Hospital Rotterdam–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kees Nooter
Department of Medical Oncology, University Hospital Rotterdam–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 61 no. 3 659-666
DOI 
https://doi.org/10.1124/mol.61.3.659
PubMed 
11854447

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Received July 5, 2001
  • Accepted December 3, 2001
  • Published online March 1, 2002.

Copyright & Usage 
The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Paul W. Schenk,
  2. Antonius W. M. Boersma,
  3. Mariël Brok,
  4. Herman Burger,
  5. Gerrit Stoter, and
  6. Kees Nooter
  1. Department of Medical Oncology, University Hospital Rotterdam–Daniel den Hoed Cancer Center, Rotterdam, the Netherlands
  1. Dr. K. Nooter, Department of Medical Oncology, University Hospital Rotterdam,Josephine Nefkens Building, Room Be422, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands. E-mail:nooter{at}oncd.azr.nl
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: February 2002 to June 2022

AbstractFullPdf
Feb 2002154930
Mar 200294920
Apr 200243534
May 200221710
Jun 200222017
Jul 200231413
Aug 20026126
Sep 200241912
Oct 200201614
Nov 20023227
Dec 20021127
Jan 20031164
Feb 20034135
Mar 200312019
Apr 2003064
May 20031107
Jun 200301011
Jul 200363818
Aug 200373016
Sep 200313288
Oct 200311364
Nov 200311273
Dec 200362610
Jan 2004132914
Feb 2004104014
Mar 200413419
Apr 200411329
May 2004104712
Jun 2004126421
Jul 200418528
Aug 2004136111
Sep 20049717
Oct 200410546
Nov 2004119211
Dec 2004156012
Jan 2005154324
Feb 2005124913
Mar 200515418
Apr 20054326
May 20054195
Jun 200517279
Jul 20057176
Aug 200510292
Sep 20056178
Oct 20059269
Nov 20057286
Dec 20055254
Jan 20063185
Feb 20067328
Mar 20064204
Apr 2006175
May 20062179
Jun 2006395
Jul 20064158
Aug 2006554
Sep 20063118
Oct 20063137
Nov 20061206
Dec 20063849
Jan 200741713
Feb 20076176
Mar 20076217
Apr 20075236
May 20074126
Jun 2007363
Jul 2007122
Aug 20073129
Sep 2007288
Oct 2007294
Nov 2007477
Dec 20070137
Jan 2008388
Feb 200821010
Mar 20082711
Apr 2008693
May 20087147
Jun 2008658
Jul 20085177
Aug 20089233
Sep 200810212
Oct 200815127
Nov 200831110
Dec 2008175
Jan 200941812
Feb 20095103
Mar 2009793
Apr 2009534
May 2009892
Jun 20094147
Jul 2009472
Aug 2009280
Sep 2009673
Oct 20091383
Nov 2009986
Dec 2009514
Jan 2010224
Feb 2010243
Mar 2010162
Apr 2010576
May 2010732
Jun 2010188
Jul 20109126
Aug 2010187
Sep 2010353
Oct 20104156
Nov 20105815
Dec 20107114
Jan 2011656
Feb 2011556
Mar 20111057
Apr 20111244
May 2011147
Jun 2011737
Jul 20111038
Aug 201151316
Sep 20111865
Oct 20116109
Nov 201138119
Dec 20112385
Jan 20121163
Feb 20121316
Mar 201226511
Apr 201213412
May 20128820
Jun 20122107
Jul 20121057
Aug 2012939
Sep 2012755
Oct 201216211
Nov 20121568
Dec 20123214
Jan 201325237
Feb 2013478
Mar 201311316
Apr 201311515
May 20135214
Jun 20137417
Jul 2013838
Aug 2013738
Sep 20132310
Oct 201313612
Nov 201310014
Dec 201316111
Jan 20141058
Feb 2014428
Mar 2014716
Apr 20141457
May 20144113
Jun 20141334
Jul 20141564
Aug 2014213
Sep 2014525
Oct 2014977
Nov 20141348
Dec 20141121
Jan 2015512
Feb 2015301
Mar 2015981
Apr 2015623
May 20151543
Jun 2015401
Jul 20152175
Aug 20151163
Sep 2015650
Oct 2015411
Nov 2015511
Dec 2015635
Jan 2016541
Feb 201610135
Mar 20161047
Apr 2016864
May 2016641
Jun 2016474
Jul 2016492
Aug 2016274
Sep 2016291
Oct 2016184
Nov 2016231
Dec 20160103
Jan 20171111
Feb 20170121
Mar 2017090
Apr 20170103
May 20170133
Jun 2017061
Jul 20170276
Aug 2017094
Sep 201701410
Oct 20170167
Nov 20170223
Dec 20170162
Jan 20180133
Feb 2018286
Mar 20182227
Apr 201802379
May 20180664
Jun 201801074
Jul 20181314
Aug 20180268
Sep 20180192
Oct 20180486
Nov 201806311
Dec 20184974
Jan 20194821
Feb 20193600
Mar 20192010
Apr 20192110
May 20192200
Jun 20193500
Jul 20194701
Aug 20198500
Sep 20192200
Oct 20191611
Nov 20191521
Dec 20192201
Jan 20202800
Feb 20201900
Mar 20201200
Apr 2020600
May 20201400
Jun 20201900
Jul 2020900
Aug 2020201
Sep 2020700
Oct 20201541
Nov 20201720
Dec 20201810
Jan 2021410
Feb 20211432
Mar 20211930
Apr 2021610
May 20211141
Jun 2021410
Jul 20211433
Aug 2021720
Sep 20211421
Oct 2021210
Nov 20211440
Dec 20211200
Jan 20221231
Feb 20221010
Mar 2022220
Apr 2022710
May 2022921
Jun 2022810

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 61 (3)
Molecular Pharmacology
Vol. 61, Issue 3
1 Mar 2002
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inactivation of the Saccharomyces cerevisiae SKY1Gene Induces a Specific Modification of the Yeast Anticancer Drug Sensitivity Profile Accompanied by a Mutator Phenotype
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Inactivation of the Saccharomyces cerevisiae SKY1Gene Induces a Specific Modification of the Yeast Anticancer Drug Sensitivity Profile Accompanied by a Mutator Phenotype

Paul W. Schenk, Antonius W. M. Boersma, Mariël Brok, Herman Burger, Gerrit Stoter and Kees Nooter
Molecular Pharmacology March 1, 2002, 61 (3) 659-666; DOI: https://doi.org/10.1124/mol.61.3.659

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Inactivation of the Saccharomyces cerevisiae SKY1Gene Induces a Specific Modification of the Yeast Anticancer Drug Sensitivity Profile Accompanied by a Mutator Phenotype

Paul W. Schenk, Antonius W. M. Boersma, Mariël Brok, Herman Burger, Gerrit Stoter and Kees Nooter
Molecular Pharmacology March 1, 2002, 61 (3) 659-666; DOI: https://doi.org/10.1124/mol.61.3.659
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • EIPA, HMA and SMN2 gene regulation
  • Clc-2 has minor role in intestinal Cl- secretion
  • Resveratrol acts as an NR4A1 antagonist in lung cancer.
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics